In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
The U.S. FDA's approval Thursday of BristolMyers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of ...
The Food and Drug Administration (FDA) approved BristolMyers Squibb’s schizophrenia drug Cobenfy Thursday — the first new approved drug for the disease in some 30 years. The drug, a combination ...
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for BristolMyers shares. The analyst notes that given that many prior antipsychotic medications ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
Some results have been hidden because they may be inaccessible to you